康泰生物：签署《许可终止协议》

Core Viewpoint - The company has terminated the licensing agreement with AstraZeneca for the development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine due to significant changes in the COVID-19 vaccine strains and market environment [1][2] Group 1 - The licensing agreement was originally signed on August 20, 2020, allowing AstraZeneca to exclusively authorize the company to develop, produce, and commercialize the vaccine in mainland China [1] - The decision to terminate the collaboration was made after careful consideration of the changes in the COVID-19 vaccine strains, market conditions, and the company's resource allocation [2] - The termination of the agreement is aligned with the company's development strategy and is not expected to have a significant impact on its production operations, core business activities, or financial status [2]